Allogene Therapeutics Announces Planned CEO Succession [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief Executive Officer and to the Board of Directors Effective July 1, 2026 SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years of leadership that established Allogene as a leader in the development of off-the-shelf cell therapies. Dr. Chang will continue to serve on the Company's Board of Directors. The Company's Board of Directors has unanimously elected Zachary Roberts, M.D., Ph.D., currently Executive Vice President, Research & Development and Chief Medical Officer, to succeed Dr. Chang as President and Chief
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation [Seeking Alpha]Seeking Alpha
- Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions [Yahoo! Finance]Yahoo! Finance
- Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Planned CEO SuccessionGlobeNewswire
ALLO
Earnings
- 5/13/26 - Beat
ALLO
Sec Filings
- 7/6/26 - Form 4
- 6/23/26 - Form 4
- 6/23/26 - Form 4
- ALLO's page on the SEC website